Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

BioSig Technologies accepts invitation to join the Alliance for Artificial Intelligence in Healthcare

Under the terms of a newly launched AI initiative, the company aims to develop novel technological solutions to improve existing therapies by combining PURE EP's electrophysiological signals and other data sources

BioSig Technologies Inc (NASDAQ:BSGM) said it has accepted an invitation to join the Alliance for Artificial Intelligence in Healthcare (AAIH).

The AAIH invite came after the company was awarded US patents for its artificial intelligence-based platform.

BioSig noted that the AAIH is the global advocacy organization for the advancement and use of AI in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems.

READ: BioSig Technologies sees its PURE EP System highlighted in new feature article in EP Lab Digest

The initiative, which was spun out from the Alliance for Regenerative Medicine, was formally launched in 2019 with 22 founders, including Amazon WS, Bayer, GE Healthcare, GlaxoSmithKline, and the University of Pittsburgh, BioSig noted.

“Artificial intelligence excels at analyzing and uncovering patterns in vast volumes of clinical data – a fundamental building block in improving patient care," said BioSig CEO Kenneth Londoner. "BioSig is a company that is committed to providing superior technological solutions based on precise signal information. We believe that a joint effort between various healthcare community representatives is a much-needed step towards solving common challenges and accelerating the adoption of AI-powered solutions."

BioSig pointed out that it recently launched a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop a next-generation AI and machine learning-powered software for the PURE EP System which provides signal information during the cardiac ablations for the treatments of arrhythmias or irregular heartbeats, a condition that affects over 33 million people worldwide.

Under the terms of the newly launched AI initiative, the company said it aims to develop novel technological solutions to improve existing therapies by combining PURE EP's electrophysiological signals and other data sources.

BioSig has also announced major strategic collaborations with other experts to further the AI- and machine-learning applications of the PURE EP System for AI technical advisory services with Harvard- and MIT-trained computer scientist and physicist, Dr Wissner-Gross.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK